RADIOACTIVE SOURCE SECURITY: WHY DO WE NOT YET HAVE A GLOBAL PROTECTION SYSTEM?
نویسندگان
چکیده
منابع مشابه
A treatment for oral precancerous lesions: why do we not yet have a treatment?
One thought kept coming back as I was preparing this presentation: “How is it possible that despite our having an early marker for oral cancer namely, oral dysplasias we are no more effective today than we were 50 years ago in the fight against oral cancer? By this I mean that the mortality rates for oral cancer have not changed in spite of the professional awareness of precancerous lesions, an...
متن کاملWhy do we not yet have a human immunodeficiency virus vaccine?
A 2-day meeting to explore why we do not yet have a human immunodeficiency virus (HIV) vaccine was held under the joint sponsorship of the Simons Center for Systems Biology at the Institute for Advanced Study and the International AIDS Vaccine Initiative, with additional support from Merck & Co., at the Institute for Advanced Study in Princeton, NJ, on 29 and 30 May 2008. The meeting brought to...
متن کاملWhy do we not have a cure for rheumatoid arthritis?
There are currently unprecedented opportunities to treat rheumatoid arthritis using well-designed, highly effective, targeted therapies. This will result in a substantial improvement in the outcome of this disorder for most affected individuals, if they can afford these therapies. Yet our lack of understanding of the basic mechanisms that initiate and sustain this disease remains a major obstac...
متن کاملWhy Do We Have Managers?
Economic actors have to make lots of decisions, and the paper is based on the premise that it takes time to be involved in any one of them. Attempts to economize on decision-making time imply that groups of peers may abdicate decision-making authority to a small set of managers even though this means that the information and preferences of the uninvolved players are neglected. We find that play...
متن کاملWhy do we still not have cardioprotective drugs?
Despite thousands of publications describing agents that limit infarct size in animals, all we have available today is reperfusion therapy. In this review, we examine why these drugs have not been translated into clinical practice. Many of the first interventions tested in clinical trials were very controversial in animal trials and their actual efficacy is still in question. Interventions base...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nuclear Engineering and Technology
سال: 2014
ISSN: 1738-5733
DOI: 10.5516/net.08.2014.713